Enoxaparin sodium

Generic Name: Enoxaparin sodium

Brand Names: Lovenox, Inhixa

Drug Type: Small Molecule

CAS Number: 9005-49-6

Unique Ingredient Identifier: E47C0NF7LV

Background: Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.

Indication: Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.

Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina

Associated Therapies: Percutaneous Coronary Intervention (PCI)

Clinical Trials

Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)

Phase 4

Recruiting

Conditions: Pregnancy, High Risk
Anticoagulants

Interventions: Drug: Lovenox

First Posted Date: 2021-04-27

Last Posted Date: 2023-05-06

Lead Sponsor: University of California, Irvine

Target Recruit Count: 12

Registration Number: NCT04861103

Locations: 🇺🇸
University of California Irvine, Orange, California, United States

LMWH for Treatment of Early Fetal Growth Restriction (HepaGrowth)

Phase 3

Conditions: Prematurity
Pre-Eclampsia
Fetal Growth Retardation

Interventions: Drug: subcutaneous Enoxaparin
Other: standard of care

First Posted Date: 2021-02-21

Last Posted Date: 2025-03-26

Lead Sponsor: Centro Hospitalar de Lisboa Central

Target Recruit Count: 12

Registration Number: NCT04762992

Locations: 🇵🇹
Centro de Diagnóstico Pré-Natal, Maternidade Dr. Alfredo da Costa, Centro Hospitalar Universitário de Lisboa Central, Lisboa, Portugal

Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19

Completed

Conditions: Hypercoagulability
Corona Virus Infection
Covid19

Interventions: Drug: Rivaroxaban
Drug: Apixaban
Drug: Enoxaparin

First Posted Date: 2021-02-03

Last Posted Date: 2022-07-20

Lead Sponsor: Ain Shams University

Target Recruit Count: 90

Registration Number: NCT04736901

Locations: 🇪🇬
Teachers Hospital, Cairo, Please Select, Egypt

Pre- Vs Postoperative Thromboprophylaxis for Liver Resection

Phase 4

Recruiting

Conditions: Liver Cancer
Surgery
Thrombosis, Deep Vein
Embolism, Pulmonary
Bleeding

Interventions: Drug: No intervention
Drug: enoxaparin or tinzaparin or dalteparin

First Posted Date: 2021-02-01

Last Posted Date: 2025-02-14

Lead Sponsor: Helsinki University Central Hospital

Target Recruit Count: 1012

Registration Number: NCT04731558

Locations: 🇳🇴
University Hospital of North Norway, Tromsø, Norway
🇫🇮
Helsinki University Hospital, Helsinki, Finland
🇫🇮
Kuopio University Hospital, Kuopio, Finland

and more 4 locations